Key facts
- Notable investors include Suzhou Oriza Holdings Corporation, Shanghai Fenglei Private Equity Fund Management, Trinity Innovation Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nexbio Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Nexbio Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nexbio Biopharmaceuticals
Developer of biopharmaceutical research and manufacturing services intended for medical research and experimental development. The company offers integrated capabilities spanning early research support, process development, analytical testing, scale-up manufacturing, quality management, and technical transfer activities across biologic modalities, with structured project coordination and regulatory-aligned practices, enabling clients with biochemical product technology.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Nexbio Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nexbio Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nexbio Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.